New studies show risk of COVID-19 hospitalization and death decreases with hydroxychloroquine use

Source: The Blaze, By Aaron Colen

Two recent studies support the effectiveness of hydroxychloroquine as a treatment for COVID-19 that can reduce the chance of hospitalization or death, refuting narratives in the media that the drug is dangerous and being pushed by President Donald Trump for political reasons.

Hydroxychloroquine is a relatively cheap and readily available drug that has been used for decades to treat malaria. Throughout the COVID-19 pandemic, doctors around the world have vouched for positive results seen in patients who take it.

What do the studies say?

study out of Italy found that HCQ reduces by 30% the risk of death for COVID-19 patients who are hospitalized. The result comes from an observational study of more than 3,400 COVID-19 patients in 33 Italian hospitals.

“We observed that patients treated with hydroxychloroquine had a 30% lower in-hospital mortality rate compared to those not receiving this treatment,” said Augusto Di Castelnuovo, epidemiologist at the Neuromed Department of Epidemiology and Prevention, currently at Mediterranea Cardiocentro in Naples.

“Our data were subjected to extremely rigorous statistical analysis, taking into account all the variables and possible confounding factors that could come into play. The drug efficacy was evaluated in various subgroups of patients. The positive results of hydroxychloroquine treatment remained unchanged, especially in those patients showing a more evident inflammatory state at the moment of admission to hospital.”

Another study, which looked at outpatient cases in New Jersey, found that a prescription of hydroxychloroquine reduced the risk of hospitalization by 47%. Because the study was conducted early in the pandemic, when mostly only symptomatic people were being tested, researchers believe their sample of more than 1,200 patients represents people with relatively more advanced cases of COVID-19.

The study concluded that hydroxychloroquine can be effective when given early after a COVID-19 diagnosis, and the study found there was no increase in negative side effects for people who took the drug. One concern about HCQ has been the potential for it to cause heart problems in some patients.

“In this observational study of 1,274 COVID-19 patients, hydroxychloroquine given as an outpatient treatment was associated with a 47% reduction in the hazard of hospitalization,” researchers wrote. “Adverse events were not increased (2% QTc prolongation events, 0% arrhythmias).”

The Food and Drug Administration has cautioned against the use of HCQ outside of hospital or clinical trial settings because of concerns about effects on the heart. The FDA revoked an emergency use authorization for the drug in June.




Related:

Covid-19: The revenge of hydroxychloroquine

Italy Study 3,451 patients: Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study

Belgium Study 8,075 patients: Low HCQ doses resulted in lower mortality in Covid patients

100 doctors go to Brasilia to order hydroxychloroquine from popular pharmacies

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »